AstraZeneca posted a loss in the second quarter as it furiously invested in its next-generation drugs while battling falling sales of its aging blockbuster Crestor, and took a restructuring charge relating to a cost-reduction program.
from WSJ.com: US Business http://ift.tt/2aM9hH7
via IFTTT
No comments:
Post a Comment